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Diffuse alveolar hemorrhage (DAH) is a rare presentation of acute pulmonary histoplasmosis. While histoplasmosis has been
reported to cause hemoptysis and alveolar hemorrhage in children, the English language literature lacks any adult case reports
documenting this association. We report a case of pulmonary histoplasmosis where the initial presentation was pneumonia with a
subsequent diagnosis of DAH.
1. Introduction
Histoplasmosis is a disease caused by the fungusHistoplasma
capsulatum [1] which can present with a varying severity of
illness ranging fromnonspecific flu-like symptoms to dissem-
inated disease with multiorgan failure. Pulmonary presen-
tations commonly include acute pneumonia with lung con-
solidation, chronic cavitary pulmonary histoplasmosis, and
pleural effusion. Complications from pulmonary histoplas-
mosis can include pericarditis, arthritis, erythema nodosum,
mediastinal fibrosis, mediastinal lymphadenitis, mediastinal
granuloma, and pulmonary nodules. Other nonpulmonary
manifestations can include central nervous system histoplas-
mosis and progressive disseminated histoplasmosis.
DAH is a rare entity that is associatedwith histoplasmosis.
Current literature lacks clinical case reports illustrating this
association in adults. As a result of this rare presentation,
a high clinical suspicion should be maintained to include
H. capsulatum in the differential diagnosis of DAH in the
appropriate clinical settings.
2. Case Description
The patient is a 71-year-old Caucasian male who presented
with a chief complaint of shortness of breath (SOB), produc-
tive cough, and dyspnea on exertion without fever. His past
medical history was remarkable only for a remote history
of smoking, tonsillectomy, and urinary retention. His family
history was positive forWegener’s granulomatosis in a sibling
and lung cancer in a parent.The patient lived inMichigan and
frequently traveled to Chicago/Illinois area. Prior to admis-
sion, the patient had been seen by his primary care physician
over the preceding 5-6 weeks for similar complaints. The
patient’s initial chest radiograph in the outpatient setting
showed patchy bilateral airspace opacities (Figure 1). He
was treated for a suspected community-acquired pneumonia
(CAP)with a course of azithromycin and a subsequent course
of moxifloxacin, with no clinical or radiologic improvement.
Upon his arrival to hospital, the patient was found to
have moderate respiratory distress. His vital signs showed
a temperature of 36.1∘C, a blood pressure of 171/88mmHg,
a heart rate of 102/min, a respiratory rate of 24/min, and
an oxygen saturation of 86% on room air. On physical
exam, the patient had bilateral wheezes and rhonchi and he
was using accessory muscles to breathe. His cardiac exam
revealed regular rhythm and tachycardia with no murmur.
The patient was started on ceftriaxone and azithromycin in
the Emergency Department. His initial laboratory workup
showed a white blood cell count of 15.8 K/𝜇L (3.8–10.6),
hemoglobin of 15.0 g/dL (13.5–17), platelet count of 220K/𝜇L
(150–450), and a creatinine of 1.0mg/dL (0.8–1.3). A chest
radiograph was remarkable for worsening airspace disease in
the right lower lung and the central left lung (Figure 2). A
computed tomography scan of the chest demonstrated diffuse
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Figure 1: Chest X-ray 5-6 weeks before admission showing bilateral
patchy lung opacities.
Figure 2: Chest X-ray on admission showing worsening bilateral
lung opacities.
lung disease, a small right pleural effusion, and enlarged
intrathoracic and lower cervical lymph nodes (Figure 3).
The patient’s respiratory status continued to decline and
he eventually required mechanical ventilation. The antimi-
crobial coverage was broadened to include vancomycin to
cover potential methicillin-resistant Staphylococcus aureus
and cefepime for Gram-negative coverage. A tapering dose
of methylprednisolone was started for a concern of possible
acute interstitial pneumonia or Wegener’s disease given the
patient’s family history.
An extensive clinical workup was initiated. A bron-
choscopy and bronchial alveolar lavage (BAL) were done
and demonstrated DAH. The sample obtained was also
noted to have vegetable material and grew alpha-hemolytic
Streptococcus and Candida albicans; cytology was negative
for malignant cells. Viral respiratory cultures for influenza,
parainfluenza, respiratory syncytial virus, and adenovirus
were all negative in the BAL, as was the Pneumocystis jirovecii
antigen. Multiple bacterial and fungal blood cultures were
negative. A nasopharyngeal swab was negative for influenza
andBordetella pertussis serology and urinary Legionella pneu-
mophila antigen were negative as well. Furthermore, antineu-
trophil cytoplasmic antibody (C-ANCA and P-ANCA) and
antinuclear antibody (ANA) were all negative.
The patient began spiking high-grade fevers (39.5∘C) and
metronidazole was added for concern of aspiration. The
Figure 3: Computed tomography on admission showing bilateral
pulmonary opacities.
patient also developed bilateral lower extremity deep vein
thromboses. A filter was placed in the inferior vena cava.
The patient continued to be febrile and developed throm-
bocytopenia (platelet count: 53 K/𝜇L) and his renal function
declined (creatinine: 3.9mg/dL). The Histoplasma urinary
antigen was positive (4.3 EIA Units, normal value <2.0
EIA Units) and the (1-3)-B-D-glucan assay was positive
(280 pg/mL, normal value <60 pg/mL). Subsequently, IV
liposomal amphotericin B was initiated (5mg/kg/day). The
patient’s methylprednisolone was maintained. The diagnosis
of acute pulmonary histoplasmosis was made based on the
geographic location, the radiological findings, the clinical
findings, and the positiveHistoplasma urinary antigen. Serum
Histoplasma antibodies obtained were negative at that time.
The hospital course was complicated by irreversible
ischemia of the right lower extremity due to a thromboem-
bolic event in the right peroneal, anterior tibial, and posterior
tibial arteries. He eventually underwent an emergent throm-
boembolectomy and fasciotomy and was given intra-arterial
tissue plasminogen activator (t-PA). A transthoracic echocar-
diogram did not reveal an evidence of valvular vegetations.
During his stay, the patient required hemodialysis, higher
ventilatory support, and blood transfusion (hemoglobin:
5.0 g/dL). The patient’s right foot became dusky and the
abdomen became distended. The patient’s clinical condition
continued to deteriorate, and he expired.
3. Discussion
Histoplasmosis is a disease caused by the fungus H. cap-
sulatum with varying clinical presentations and severity of
the illness [1]. H. capsulatum is found in soil and material
contaminated with bird or bat droppings often associated
with caves, bats, and bird roosts [1].
Histoplasmosis infection tends to occur within twoweeks
after an inhalation exposure to H. capsulatum. The acute
phase of infection is characterized by nonspecific flu-like
symptoms and cough, oftenwith a normal appearingCXR [1].
The severity of the disease varies depending on the exposure
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intensity, the pathogen inoculum, host immunity, and the
presence of underlying structural lung disease [2].
Histoplasmosis by definition includes primary pul-
monary histoplasmosis, with acute or chronic cavitary forms,
progressive disseminated histoplasmosis with multiorgan
involvement, and central nervous system (CNS) histoplasmo-
sis. Othermanifestations associated with histoplasmosis have
been reported as previously mentioned [3].
DAH is a severe and life-threatening acute condition
associated with bleeding into the alveoli related to the
breakdown in the alveolar-capillary basement membrane
secondary to an injury or inflammation of the blood ves-
sels. The differential diagnosis for DAH is broad and can
broadly be categorized in the following groups: vasculitis
or capillaritis, “bland” pulmonary hemorrhage, and alveolar
bleeding associated with another process or condition [4].
Capillaritis is a pathological process characterized by neu-
trophilic infiltration of the pulmonary interstitium. Bland
pulmonary hemorrhage is characterized by bleeding into the
alveolar spaces without associated vasculitis or capillaritis
[4]. Our patient was diagnosed with DAH based of diffuse
infiltrates on imaging, hemoglobin drop (15 to 5 g/dL), and
bronchoscopy findings of blood in the alveoli. Patients with
DAHgenerally present with nonspecific signs and symptoms.
In patients with DAH, a high clinical suspicion should be
maintained to include the possible diagnosis of histoplasmo-
sis in the appropriate clinical setting.
Histoplasmosis has been previously reported as an eti-
ology for hemoptysis and pulmonary hemorrhage [5] but,
to our knowledge, no cases have been reported in the adult
literature.
The diagnosis of Histoplasmosis requires a good clinical
history, physical exam, imaging studies, and laboratory stud-
ies includingmicrobiological, serological, and histopatholog-
ical testing [6].
Histoplasma antigen can be detected in the urine and/or
serum. Antigenuria was detected in up to 91.8% of the
disseminated cases with higher detection rates when using
the newer generation testing methods, in immunocompro-
mised patients, and in patients with higher antigen titers
[6]. Antigenuria is also detected at higher rates in patients
with severe disease as compared to mild disease (100%
versus 78.7%, resp.), as well as in patients with disseminated
histoplasmosis infection [6]. Antigen detection is helpful in
making the diagnosis before the antibodies turn positive in
the serum [7], as seroconversion might take up to 3 months
after acute pulmonary histoplasmosis [7].
In our case, imaging studies in combination with bron-
choscopy led to the diagnosis of DAH. Extensive workup
failed to identify a viral cause or bacterial cause other than
alpha-hemolytic Streptococcus and rheumatologic investiga-
tion did not support the diagnosis of Wegener’s disease. The
patient’s urinary Histoplasma antigen test was positive, thus
establishing the diagnosis of acute pulmonary histoplasmosis
in the absence of positive serum antibodies; this dissociation
is explained by the earlier positivity of the antigen test before
seroconversion.
Most H. capsulatum infections are self-limited and
resolve without antifungal therapy. Current clinical practice
guidelines from the Infectious Diseases Society of America
(IDSA) recommend various treatment regimens depending
on the type of disease [1]. Definitive indications for antifun-
gal therapy include acute diffuse pulmonary infection with
moderate-to-severe symptoms, chronic cavitary pulmonary
infection, progressive disseminated infection, andCNS infec-
tion [1]. Other potential indications for antifungal therapy
include acute focal pulmonary infection, asymptomatic cases,
mild symptoms that persist for >1 month, mediastinal lym-
phadenitis, mediastinal granuloma, or inflammatory syn-
dromes treated with corticosteroids [1]. Clinical conditions
typically not recommended to be treated with antifungal
therapy include mediastinal fibrosis, pulmonary nodules,
broncholithiasis, and presumed ocular histoplasmosis syn-
drome [1].
The standard treatment for moderately severe-to-severe
acute pulmonary disease is lipid amphotericin B (AmB) (3.0–
5.0mg/kg daily) or deoxycholate AmB (0.7–1.0mg/kg daily)
for 1-2 weeks, followed by itraconazole (200mg twice daily for
a total of 12 weeks) and methylprednisolone (0.5–1.0mg/kg
daily intravenously for 1-2 weeks) [1]. Similarly, the treatment
of progressive disseminated histoplasmosis that ismoderately
severe-to-severe is liposomal AmB (3.0mg/kg daily), AmB
lipid complex (5.0mg/kg daily), or deoxycholate AmB (0.7–
1.0mg/kg daily) for 1-2 weeks, followed by itraconazole
(200mg twice daily for at least 12 months) [1].
Amphotericin B in any formulation is rarely used as
a single agent therapy and most patients are switched to
itraconazole for the remainder of the therapy. In patients
in whom the use of itraconazole is contraindicated or not
tolerated, other azoles may be used as second-line therapies.
Fluconazole has been used successfully as an alternative ther-
apy to itraconazole. Furthermore, there have been reported
cases of the newer azoles, posaconazole, and voriconazole,
successfully treating various types of histoplasmosis infec-
tions [8]. Antigenuria can be used to follow the response to
treatment; if antigen levels do not decline, it may indicate a
treatment failure. Levels of urine antigen should be checked
before treatment is begun, at 2 weeks and 1 month of
treatment, every 3 months thereafter during the course of
therapy, and at 6 months after the treatment is completed
[1]. Decreasing antigen levels indicate response to treat-
ment, while increasing levels often indicate possible relapse.
The persistence of low-level antigenuria does not require
extending the treatment course if the patient has clinically
responded to therapy and received adequate duration of
therapy.
Our patient was started on amphotericin B therapy
(liposomal AmB: 5mg/kg/day) with an initial improvement
and resolution of his fever. Lipid formulation of ampho-
tericin B was selected given the recent renal impairment
to minimize additional nephrotoxicity. In addition, he was
continued on treatment with methylprednisolone. Other
events complicated the hospital course and the patient
expired.
This clinical case report illustrates the rare association
between H. capsulatum and DAH and the first adult case
reported in the English language literature to our knowl-
edge. In light of the potential life-threatening nature of
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this association, H. capsulatum should be considered in the
appropriate epidemiological and clinical settings.
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